← Leaderboards
Nicholas Venetos
Case Western Reserve University
$212,958
Attributed
$212,958
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $54.5K · FY2022–25$100K$75K$50K$25K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$212,958 · 1
By mechanism
F30$212,958 · 1
Top collaborators
No co-investigators on record.
Most similar at Case Western Reserve University
Same institution · by research overlap
- Jonathan S. Stamler$32,849,627
- Hualin Zhou$2,102,018
- Thomas Michael Raffay$2,146,362
- Sanford D Markowitz$49,710,196
- Amitabh Chak$17,077,792
Others in their field
Other Rising Stars on “Equilibrium”
- John Alam · Eip Pharma, Inc.$10,411,018
- Fumiaki Yokokawa · University Of Texas Med Br Galveston$7,180,989
- Sabrina Paganoni · Massachusetts General Hospital$6,045,501
- Suma Babu · Massachusetts General Hospital$6,045,501
- Raul Padron · Univ Of Massachusetts Med Sch Worcester$4,501,962
- Vidmantas Petraitis · Hackensack University Medical Center$3,590,433
Research focus
EquilibriumEtiologyAcetyl-Coa CarboxylaseAffectAblationEnzymesAtp Citrate (Pro-S)-LyaseAttenuatedBody WeightCell Culture TechniquesCellsAmino AcidsAnimalsCoenzyme ACoupledCrispr/Cas TechnologyCysteineDietDietaryDietary AdministrationDiet-Induced ObesityDrug TargetingEffective TherapyFamily
Grant awards (4)
AKR1a1 as a novel therapeutic target for Non-Alcoholic Fatty Liver Disease$54,538
F30 · FY2025 · DK · contact PI
AKR1a1 as a novel therapeutic target for Non-Alcoholic Fatty Liver Disease$53,974
F30 · FY2024 · DK · contact PI
AKR1a1 as a novel therapeutic target for Non-Alcoholic Fatty Liver Disease$52,694
F30 · FY2023 · DK · contact PI
AKR1a1 as a novel therapeutic target for Non-Alcoholic Fatty Liver Disease$51,752
F30 · FY2022 · DK · contact PI